Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature
- PMID: 30616415
- DOI: 10.1080/10428194.2018.1562185
Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature
Comment in
-
Antibody-based therapy in acute leukemia - beware the risks.Leuk Lymphoma. 2019 Jul;60(7):1608-1609. doi: 10.1080/10428194.2019.1608535. Epub 2019 Jun 17. Leuk Lymphoma. 2019. PMID: 31204877 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical